Estimates Revisions NewAmsterdam Pharma Company N.V. Deutsche Boerse AG
Stocks
KH6
NL00150012L7
Biotechnology & Medical Research
|
Market Closed -
Deutsche Boerse AG
16:25:02 28/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 19.06 EUR | -3.03% |
|
+1.49% | -32.41% |
| 09-22 | European Commission Approves Obicetrapib for Primary Hypercholesterolemia | MT |
| 09-21 | NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Frazier Lifesciences Acquisition Corporation(NAMS)
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Data source:
Frazier Lifesciences Acquisition Corporation(NAMS)
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Frazier Lifesciences Acquisition Corporation(NAMS)
EBIT
Dividend / Share (DPS)
Data source:
Frazier Lifesciences Acquisition Corporation(NAMS)
Cash or Net Debt
- Stock Market
- Stocks
- NAMS Stock
- KH6 Stock
- Consensus NewAmsterdam Pharma Company N.V.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
